Literature DB >> 23392460

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.

Andrew Zolopa1, Paul E Sax, Edwin DeJesus, Anthony Mills, Calvin Cohen, David Wohl, Joel E Gallant, Hui C Liu, Andrew Plummer, Kirsten L White, Andrew K Cheng, Martin S Rhee, Javier Szwarcberg.   

Abstract

We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF, n = 352). At week 48, EVG/COBI/FTC/TDF was noninferior to EFV/FTC/TDF (88% vs 84%, difference +3.6%, 95% confidence interval: -1.6% to 8.8%). Virologic success (HIV-1 RNA <50 copies/mL) was maintained at week 96 (84% vs 82%, difference +2.7%, 95% CI: -2.9% to 8.3%). Discontinuation due to adverse events was low (5% vs 7%). Median changes in serum creatinine (mg/dL) at week 96 were similar to week 48. These results support the durable efficacy and long-term safety of EVG/COBI/FTC/TDF.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23392460     DOI： 10.1097/QAI.0b013e318289545c

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


  57 in total

1.  Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.

Authors:  Melissa Wares; Said Hassounah; Thibault Mesplède; Paul A Sandstrom; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

2.  Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.

Authors:  Georg Behrens; Bart Rijnders; Mark Nelson; Chloe Orkin; Calvin Cohen; Anthony Mills; Richard A Elion; Simon Vanveggel; Marita Stevens; Laurence Rimsky; David Thorpe; Matthew Bosse; Kirsten White; Lijie Zhong; Jennifer DeMorin; Susan K Chuck
Journal:  AIDS Patient Care STDS       Date:  2014-03-24       Impact factor: 5.078

3.  Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.

Authors:  Thibault Mesplède; Nathan Osman; Melissa Wares; Peter K Quashie; Said Hassounah; Kaitlin Anstett; Yingshan Han; Diane N Singhroy; Mark A Wainberg
Journal:  J Antimicrob Chemother       Date:  2014-06-10       Impact factor: 5.790

4.  Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings.

Authors:  Robin M Nance; Vani Vannappagari; Kimberly Smith; Catherine B Johannes; Brian Calingaert; Catherine W Saltus; Kenneth H Mayer; Bridget M Whitney; Benigno Rodriguez; Richard D Moore; Joseph J Eron; Elvin Geng; William Christopher Mathews; Michael J Mugavero; Michael S Saag; Mari M Kitahata; Joseph A C Delaney; Heidi M Crane
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

5.  Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection.

Authors:  William R Truong; Jason J Schafer; William R Short
Journal:  P T       Date:  2015-01

6.  Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.

Authors:  Kenneth H Mayer; Daniel Jones; Catherine Oldenburg; Sachin Jain; Marcy Gelman; Shayne Zaslow; Chris Grasso; Matthew J Mimiaga
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

Review 7.  HIV-associated lipodystrophy: impact of antiretroviral therapy.

Authors:  Giovanni Guaraldi; Chiara Stentarelli; Stefano Zona; Antonella Santoro
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

8.  Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens.

Authors:  Amedeo De Nicolò; Marco Simiele; Andrea Calcagno; Adnan Mohamed Abdi; Stefano Bonora; Giovanni Di Perri; Antonio D'Avolio
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

9.  A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.

Authors:  Selly Ba; Dana N Raugi; Robert A Smith; Fatima Sall; Khadim Faye; Stephen E Hawes; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

10.  HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study.

Authors:  Robin M Nance; J A Chris Delaney; Jane M Simoni; Ira B Wilson; Kenneth H Mayer; Bridget M Whitney; Frances M Aunon; Steven A Safren; Michael J Mugavero; W Christopher Mathews; Katerina A Christopoulos; Joseph J Eron; Sonia Napravnik; Richard D Moore; Benigno Rodriguez; Bryan Lau; Rob J Fredericksen; Michael S Saag; Mari M Kitahata; Heidi M Crane
Journal:  Ann Intern Med       Date:  2018-08-21       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.